Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Bio Green Med Solution, Inc. Director's Dealing 2023

Jul 3, 2023

35092_dirs_2023-07-03_fc200008-a17d-425e-8a8e-4231eb54e760.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cyclacel Pharmaceuticals, Inc. (CYCC)
CIK: 0001130166
Period of Report: 2023-06-30

Reporting Person: Kirschbaum Mark (Chief Medical Officer)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2023-06-30 Stock Option (right to buy) $0.5891 A 70200 Acquired 2033-06-30 Common Stock (70200) Direct

Footnotes

F1: The reporting person received an award of 70,200 options on June 30, 2023, which shall vest in full on June 30, 2026, provided, however, that if certain clinical milestones are achieved then such options shall vest in full earlier in connection with such achievement.